Membrane-Bound IL-15-IL-15Rα Chimeric Receptor for T-Cell Persistence

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Certain cancers induce an immunosuppressive microenvironment that reduces the robustness of antitumor immune responses, posing challenges for cellular immunotherapies such as CAR T cell therapy and NK cell-based treatments.

Innovation Solution

Development of a membrane-bound IL-15-IL-15Rα sushi domain chimeric receptor to enhance cytokine signaling in T cells and NK cells, comprising specific amino acid sequences and linkers, which can be expressed in immune cells to improve their function and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If cytokines are used to expand T cells, then T cell quantity increases, but T cell exhaustion and diminished persistence occur

Engineering Contradiction:
ImproveT cell quantityVSAvoidT cell persistence
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent combines multiple cytokine functions (IL-15 for survival/proliferation and IL-21 for differentiation) into a single chimeric receptor construct. This merging allows simultaneous delivery of multiple cytokine signals through one receptor, achieving T cell expansion and persistence without the harmful effects of individual cytokine overstimulation

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The chimeric receptor acts as an intermediary between cytokines and their native receptors. By fusing IL-15 and IL-21 signaling domains into a single receptor that can be engineered into T cells, the patent creates a controlled mediator that delivers cytokine signals in a regulated manner, avoiding the uncontrolled stimulation that leads to exhaustion

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If multiple cytokines are used together to improve CAR-T potency, then immune response quality improves, but system complexity increases

Engineering Contradiction:
ImproveCAR-T potencyVSAvoidcytokine combination system
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges IL-15 and IL-21 signaling capabilities into a single chimeric receptor molecule. This consolidation reduces the complexity of delivering and coordinating multiple separate cytokine treatments while maintaining the synergistic effects needed for improved CAR-T potency and persistence

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The chimeric receptor enhances the potency and persistence of T cells and NK cells, improving the effectiveness of immunotherapies against cancer by inducing a robust immune response.

Implementation Method 1

Since overall T cell function and proliferation are dependent on cytokine signaling, it is theorized that the use of cytokines may improve the overall quality and potency of T cell based therapies

Methodology Applied
Scientific EffectCytokine signaling:

Data Source

PatentUS12454563B2Immune cell function
Publication Date: 2025.10.28 KITE PHARMA INC

AI summary

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of cytokine signaling. Disclosed are embodiments of a membrane bound interleukin 15 (IL-15)-IL-15Ralpha sushi domain chimeric receptor. The chimeric receptor may comprise a FAS transmembrane domain or an IL-7 transmembrane domain. Different embodiments of the chimeric receptor have different polypeptide lengths between the IL-15 region and the transmembrane domain.